A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)

Recruiting

Phase 1

MK-5684A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06814132

Conditions

Kidney Failure, Chronic

End-Stage Kidney Disease

Renal Failure, Chronic

Renal Failure, End-Stage

Healthy Participants

Eligibility Criteria

Sex: Male

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

MK-5684

Prednisone

Fludrocortisone acetate

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-05-12.